ISSN 1662-4009 (online)

ey0016.9-7 | Metabolic and Cardiovascular Risk in Cancer Survivors | ESPEYB16

9.7. No evidence of overweight in long-term survivors of childhood cancer after glucocorticoid treatment

FN Belle , R Kasteler , C Schindera , M Bochud , RA Ammann , NX von der Weid , CE Kuehni , Swiss Pediatric Oncology Group (SPOG)

To read the full abstract: Cancer. 2018 Sep 1; 124 (17): 3576.Glucocorticoids still represent one of the pillars in the treatment of paediatric hematologic malignancies, but they cause excessive weight gain through several mechanisms. However, it is unclear whether these glucocorticoids have a long-lasting effect on body weight, because studies have focused mainly on the acute effects du...

ey0018.4-6 | Growth Hormone Therapy: Safety | ESPEYB18

4.6. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study

L Savendahl , R Cooke , A Tidblad , D Beckers , G Butler , S Cianfarani , P Clayton , J Coste , ACS Hokken-Koelega , W Kiess , CE Kuehni , K Albertsson-Wikland , A Deodati , E Ecosse , R Gausche , C Giacomozzi , D Konrad , F Landier , R Pfaeffle , G Sommer , M Thomas , S Tollerfield , GRJ Zandwijken , JC Carel , AJ Swerdlow

Lancet Diabetes Endocrinol. 2020;8(8):683–692. doi: 10.1016/S2213-8587(20)30163-7. PMID: 32707116SAGhE is a large independent European consortium including eight different countries (Belgium, France, Germany, Italy, The Netherlands, Sweden, Switzerland, and the UK) which was set up to evaluate the long-term safety of rhGH in a large cohort (>24 000) of young adult patients t...